naronapride

Naronapride is an orally bioavailable, small molecule drug designed as a potent and selective serotonin 5-HT4 receptor agonist and dopamine D2 receptor antagonist. It acts locally in the gastrointestinal (GI) tract to promote motility by stimulating acetylcholine release via 5-HT4 activation and removing inhibitory effects on motility through D2 antagonism. Naronapride is being developed primarily for gastroesophageal reflux disease (GERD), especially in patients not responsive to proton pump inhibitors (PPIs), as well as for gastroparesis, chronic idiopathic constipation, erosive esophagitis, and irritable bowel syndrome with constipation (IBS-C). The drug has demonstrated dose-dependent acceleration of gastric emptying in clinical studies and has shown a favorable safety profile with minimal systemic absorption. Naronapride was originally developed by ARYx Therapeutics and is currently being advanced by Renexxion and Dr Falk Pharma[1][3][6][7].

Other names

naronapridum